By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – XDx today said that Aetna has determined that the firm's AlloMap test is medically necessary for monitoring rejection in heart transplant recipients more than a year after a heart transplant.
Registering provides access to this and other free content.
Already have an account?Login Now.
Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.
In Nature this week: genetic history of HIV in the US, and more.
There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.
A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.